Gene Expression Signatures Can Aid Diagnosis of Sexually Transmitted Infection-Induced Endometritis in Women

Xiaojing Zheng1*, Catherine M. O'Connell1, Wujuan Zhong2, Taylor B. Poston1, Harold C. Wiesenfeld3,4, Sharon L. Hillier3,4, Maria Trent5, Charlotte Gaydos6, George Tseng7, Brandie D. Taylor8 and Toni Darville1*

1 Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 2 Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 3 Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, Pittsburgh, PA, United States, 4 Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA, United States, 5 Section on Adolescent Medicine, Department of Pediatrics, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, United States, 6 Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, United States, 7 Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, United States, 8 Department of Epidemiology and Biostatistics, Texas A&M University, College Station, TX, United States

Sexually transmitted infection (STI) of the upper reproductive tract can result in inflammation and infertility. A biomarker of STI-induced upper tract inflammation would be significant as many women are asymptomatic and delayed treatment increases risk of sequelae. Blood mRNA from 111 women from three cohorts was profiled using microarray. Unsupervised analysis revealed a transcriptional profile that distinguished 9 cases of STI-induced endometritis from 18 with cervical STI or uninfected controls. Using a hybrid feature selection algorithm we identified 21 genes that yielded maximal classification accuracy within our training dataset. Predictive accuracy was evaluated using an independent testing dataset of 5 cases and 10 controls. Sensitivity was evaluated in a separate test set of 12 women with asymptomatic STI-induced endometritis in whom cervical burden was determined by PCR; and specificity in an additional test set of 15 uninfected women with pelvic pain due to unknown cause. Disease module preservation was assessed in 42 women with a clinical diagnosis of pelvic inflammatory disease (PID). We also tested the ability of the biomarker to discriminate STI-induced endometritis from other diseases. The biomarker was 86.7% (13/15) accurate in correctly distinguishing cases from controls in the testing dataset. Sensitivity was 83.3% (5/6) in women with high cervical Chlamydia trachomatis burden and asymptomatic endometritis, but 0% (0/6) in women with low burden. Specificity in patients with non-STI-induced pelvic pain was 86.7% (13/15). Disease modules were preserved in all 8 biomarker predicted cases. The 21-gene biomarker was highly discriminatory for systemic infections, lupus, and appendicitis, but wrongly predicted...
tuberculosis as STI-induced endometritis in 52.4%. A 21-gene biomarker can identify asymptomatic women with STI-induced endometritis that places them at risk for chronic disease development and discriminate STI-induced endometritis from non-STI pelvic pain and other diseases.

Keywords: biomarker, mRNA, Chlamydia, gonorrhea, pelvic inflammatory disease

INTRODUCTION

Pelvic inflammatory disease (PID) occurs when sexually transmitted pathogens ascend from the cervix to the uterus and oviducts, resulting in endometritis and salpingitis. Infection with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), or both, may lead to PID and associated morbidities including infertility, ectopic pregnancy, and chronic pelvic pain. Mycoplasma genitalium has emerged as a pathogen causing PID and its associated long-term complications (McGowin and Anderson-Smith, 2011; Bjartling et al., 2012). PID affects approximately 800,000 women annually in the United States (Centers for Disease Control Prevention, 2017), and yearly medical expenditures for PID treatment approach ~2 billion dollars (Rein et al., 2000).

The diagnosis of PID is imprecise. No single historical, physical, or laboratory finding is both sensitive and specific for the diagnosis of PID (Workowski et al., 2015). A major barrier to the prevention of morbidities is delayed diagnosis due to absence of or presence of mild non-specific symptoms (Wiesenfeld et al., 2005). Still, both clinical and subclinical upper tract inflammation can lead to chronic sequelae (Wiesenfeld et al., 2012). Laparoscopy with coincident biopsies of the endometrium and oviducts can confirm endometritis and salpingitis but this procedure is invasive and requires general anesthesia. Endometrial biopsy via suction catheter can be used to obtain tissue for use in the diagnosis of endometrial infection and inflammation associated with reduced fertility (Wiesenfeld et al., 2012). In fact, histologic endometritis is highly predictive of salpingitis and endometrial biopsy provides a specific diagnosis of PID (Kiviat et al., 1990). Although minimally invasive, the endometrial biopsy procedure is not routinely used for the diagnosis of endometritis because it requires trained clinicians and the biopsy procedure is invasive. A biomarker that identifies women with subclinical PID would significantly improve diagnosis and case management and could be used as a surrogate of upper reproductive tract disease for evaluation of STI therapeutics and vaccines (Poston et al., 2017).

We reported a distinct blood-derived mRNA profile in women with symptomatic PID and endometritis caused by GC and/or CT. Women with STI-induced endometritis exhibited enhanced expression of myeloid cell genes with suppression of genes involved in protein synthesis, mitochondrial oxidative phosphorylation, and T-cell responses compared to uninfected women or women with cervical infection only (Zheng et al., 2018). Women solely infected with CT expressed elevated levels of type I and type II interferon genes. The present study extends these findings by identifying a 21-gene blood biomarker that can aid prediction of STI-induced endometritis in symptomatic and asymptomatic women. Although insensitive for asymptomatic women with endometritis and low cervical burden, biomarker sensitivity for women with endometritis and high cervical burden was 83.3% (5/6). This biomarker distinguished women with STI-induced endometritis from patients with non-STI-induced pelvic pain, disseminated bacterial infections, lupus, and appendicitis, but failed to distinguish patients with tuberculosis, where a subset of the 21-gene set was also dysregulated.

METHODS

This study complied with the Declaration of Helsinki guidelines and all study participants provided written informed consent prior to initiation of study procedures. The Institutional Review Boards for Human Subject Research at the University of Pittsburgh, the University of North Carolina, and Johns Hopkins University approved the study.

Study Population

This study used whole blood collected from female participants recruited into three independent cohorts. The Anaerobes and Clearance of Endometritis (ACE) cohort was comprised of symptomatic women with clinically diagnosed PID, according to the Centers for Disease Control and Prevention diagnostic criteria (Workowski et al., 2015), who participated in a clinical trial (NCT01160640) comparing antibiotic regimens for PID treatment (Zheng et al., 2018). Diagnostic criteria included one or more of the following present on pelvic examination: cervical motion tenderness, or uterine tenderness or adnexal tenderness, in a sexually active young woman experiencing pelvic or lower abdominal pain (Workowski et al., 2015). The T cell Response Against Chlamydia (TRAC) cohort was comprised of asymptomatic women at high risk for STI (Russell et al., 2016). Both cohorts were recruited from clinics and emergency departments in Pittsburgh, PA. The Technology Enhanced Community Health-Nursing (TECH-N) cohort was comprised of women with clinical PID participating in a clinical trial of a nursing text-messaging intervention in Baltimore, MD (NCT01640379) (Trent et al., 2016).

Data Collection

As described previously for both ACE and TRAC, at enrollment, demographic data, a standardized medical history, and general physical and pelvic exams were performed. Cervical swabs were collected for microbiological molecular testing. Blood was collected for transcriptional profiling, and endometrial sampling was performed for microbiologic and histologic evaluation (Zheng et al., 2018); endometritis was defined according to published criteria (Kiviat et al., 1990). Chlamydial cervical
burden was estimated via quantitative PCR using DNA extracted from reserved cervical swab eluates (Russell et al., 2016). The median cervical burden for the TRAC cohort = $10^4$ genome equivalents/swab (Russell et al., 2016); high and low burden were defined as values above and below this level, respectively. For patients in TECH-N, clinical, cervical microbiological, and blood transcriptional data were collected, but endometrial biopsy was not performed.

### Microarray Data Acquisition and Processing

Total RNA was isolated from blood of TECH-N participants and analyzed via microarray (Illumina Human HT12 v3.0 expression bead chip) in the Genomics and Proteomics Core Laboratories at the University of Pittsburgh as described previously (Zheng et al., 2018) for ACE and TRAC participants and can be accessed from GEO (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110106). Transcripts were quantile normalized (Irizarry et al., 2003) and log2 transformed. Genes were filtered by expression ($\mu > 6.8$) and variance thresholds ($\sigma^2 > 0.25$). Batch effects were measured by guided PCA (Reese et al., 2013), and corrected using ComBat (Johnson et al., 2007). A total of 4952 transcripts passed initial filtering criteria. The GSE19491 study was performed using Illumina HT V3 chips ($\sim 48,000$ probes), our data (GSE110106) and the GSE83091 dataset were derived using Illumina HT V4 chips ($\sim 47,000$ probes). The arrays share an overlapping set of $\sim 40,000$ probes. All data were quantile normalized and standardized.

### Study Design

Cases were previously defined as women with a clinical PID diagnosis and biopsy-confirmed endometrial CT/GC (STI) and endometritis, and controls as study participants who did not display symptoms of PID, lacked endometrial infection and inflammation, and included women with cervical CT/GC and uninfected women (Zheng et al., 2018). For this study, two-thirds of cases and controls were assigned to a training dataset and the remaining one-third to a testing dataset based on the temporal order in which they were enrolled (Figure 1). The training dataset was used to derive a biomarker, that was then tested on the remaining cases and controls (testing dataset).

Study participants categorized as subclinical PID ($N = 12$) were asymptomatic with biopsy-confirmed endometrial CT/GC and endometritis. Symptomatic/No STI indicates women with clinical PID symptoms not infected with STI pathogens ($N = 15$). These independent groups were used to test the sensitivity and the specificity of the biomarker, respectively. An additional cohort of participants in TECH-N were used to test for preservation of disease modules ($N = 42$) (Figure 1).

Lastly, we tested the ability of the biomarker to discriminate STI-induced endometritis from other diseases including staphylococcal ($N = 40$) and streptococcal infections ($N = 12$), lupus ($N = 28$), appendicitis ($N = 20$), and tuberculosis ($N = 82$); and controls for staphylococcal and streptococcal infections ($N = 23$), controls for lupus ($N = 17$) and controls for tuberculosis ($N = 40$) using array data retrieved from GEO.

FIGURE 1 | Diagram of study organization. Blood transcriptional mRNA profiles from cases and controls were analyzed in a training dataset, identified classifier genes were subsequently validated in an independent testing dataset. The classifier genes were also evaluated in three additional independent patient datasets for sensitivity, specificity, and disease module preservation, respectively. ¹Cases: women with symptoms consistent with PID and with biopsy confirmed endometrial STI with N. gonorrhoeae and/or C. trachomatis and/or M. genitalium and endometritis. ²Controls: asymptomatic women who were uninfected or infected at the cervix only, with no endometrial inflammation. *Participants recruited from TRAC cohort. ‡Participants recruited from ACE cohort. ***Participants recruited from TECH-N cohort comprised women with symptoms of PID who had cervical microbiology determined but lacked endometrial data.
TABLE 1 | Demographic, clinical, and microbiological characteristics of training and testing datasets.

|                              | Training dataset (N = 27) | Testing dataset (N = 15) |
|------------------------------|----------------------------|----------------------------|
|                              | Case | Control | P value | Case | Control | P value |
| Number of subjects           | 9    | 18      | 0.288   | 5    | 10      | 0.117   |
| Age, y, median (range)       | 23 (20–37) | 21 (18–35) | 0.0106  | 21 (18–25) | 19 (18–22) | 0.341   |
| Race                         |      |         |         |      |         |         |
| African American             | 3 (33) | 10 (56) | 0.0106  | 5 (100) | 6 (60)  | 0.341   |
| White                        | 5 (56) | 2 (11)  | 0.0106  | 0 (0)  | 0 (0)   | 0.0106  |
| American Indian/Alaska Native| 0 (0)  | 1 (6)   | 0.0106  | 0 (0)  | 0 (0)   | 0.0106  |
| Multiracial                  | 1 (11) | 5 (28)  | 0.0106  | 0 (0)  | 3 (30)  | 0.341   |
| Other                        | 0 (0)  | 0 (0)   | 0.0106  | 0 (0)  | 1 (10)  | 0.341   |
| Ethnicity                    |      |         | 0.333   |      |         | 0.524   |
| Hispanic or Latino           | 1 (11) | 0 (0)   | 0.333   | 0 (0)  | 2 (20)  | 0.524   |
| Not Hispanic or Latino       | 8 (89)| 18 (100)| 0.333   | 5 (100)| 8 (80)  | 0.524   |
| Marital status               |      |         | 0.628   |      |         | 1       |
| Single                       | 8 (89)| 13 (72) | 0.628   | 5 (100)| 9 (90)  | 1       |
| Living with partner (at least 4 months) | 1 (11) | 5 (28)  | 0.628   | 0 (0)  | 1 (10)  | 1       |
| Education level              |      |         | 0.36    |      |         | 0.417   |
| <HS graduate                 | 2 (22)| 3 (17)  | 0.36    | 0 (0)  | 2 (20)  | 0.417   |
| HS graduate of GED           | 2 (22)| 8 (44)  | 0.36    | 3 (60) | 4 (40)  | 0.417   |
| some college                 | 2 (22)| 6 (33)  | 0.36    | 1 (20) | 4 (40)  | 0.417   |
| college graduate             | 2 (22)| 1 (6)   | 0.36    | 0 (0)  | 0 (0)   | 0.417   |
| vocational                   | 1 (12)| 0 (0)   | 0.36    | 1 (20) | 0 (0)   | 0.417   |
| Insurance                    |      |         | 0.439   |      |         | 0.529   |
| None                         | 1 (11)| 6 (33)  | 0.439   | 3 (60) | 1 (10)  | 0.529   |
| Private                      | 3 (33)| 2 (11)  | 0.439   | 0 (0)  | 1 (10)  | 0.529   |
| Public                       | 0 (0) | 0 (0)   | 0.439   | 0 (0)  | 1 (10)  | 0.529   |
| Don't know                   | 0 (0) | 0 (0)   | 0.439   | 0 (0)  | 1 (10)  | 0.529   |
| Medicaid HMO                 | 5 (56)| 9 (50)  | 0.439   | 2 (40) | 5 (50)  | 0.529   |
| Other                        | 0 (0) | 1 (6)   | 0.439   | 0 (0)  | 1 (10)  | 0.529   |
| *Trichomonas vaginalis*      |      |         | 0.268   |      |         | 1       |
| Yes                          | 0 (0) | 4 (22)  | 0.268   | 0 (0)  | 0 (0)   | 1       |
| No                           | 9 (100)| 14 (78)| 0.268   | 5 (100)| 10 (100)| 1       |
| *Bacterial vaginosis*        |      |         | 0.106   |      |         | 0.1305  |
| Nugent Score 0–3             | 1 (11)| 7 (39)  | 0.106   | 1 (20) | 6 (60)  | 0.1305  |
| Nugent Score 4–6             | 1 (11)| 5 (28)  | 0.106   | 0 (0)  | 2 (20)  | 0.1305  |
| Nugent Score 7–10            | 7 (78)| 6 (33)  | 0.106   | 4 (80) | 2 (20)  | 0.1305  |
| *Contraception*              |      |         | 0.333   |      |         | 0.524   |
| Oral contraceptive pill      |      |         | 0.333   |      |         | 0.524   |
| Yes                          | 1 (11)| 0 (0)   | 0.333   | 0 (0)  | 2 (20)  | 0.524   |
| No                           | 8 (89)| 18 (100)| 0.333   | 5 (100)| 8 (80)  | 0.524   |
| Depot medroxyprogesterone acetate |      |         | 1       |      |         | 0.6     |
| Yes                          | 0 (0) | 1 (6)   | 1       | 1 (20) | 4 (40)  | 0.6     |
| No                           | 9 (100)| 17 (94)| 1       | 4 (80) | 6 (60)  | 0.6     |
| Intrauterine device          |      |         | 0.333   |      |         | 1       |
| Yes                          | 1 (11)| 0 (0)   | 0.333   | 0 (0)  | 0 (0)   | 1       |
| No                           | 8 (89)| 18 (100)| 0.333   | 5 (100)| 10 (100)| 1       |
| Condoms                      |      |         | 0.695   |      |         | 1       |
| Yes                          | 4 (44)| 10 (56)| 0.695   | 4 (80) | 7 (70)  | 1       |
| No                           | 5 (56)| 8 (44) | 0.695   | 1 (20) | 3 (30)  | 1       |
**Unsupervised Hierarchical Clustering, Principal Component Analysis (PCA), Classifier Identification and Validation**

We applied unsupervised cluster analysis and PCA to identify reliable disease subgroups. For hierarchical clustering, genes were clustered via Pearson correlation, while samples were clustered using Spearman's rank correlation with average linkage criterion. To identify classifiers, a hybrid feature selection algorithm which combines two feature selection methods—the filter (moderate t statistics) and the wrapper (mSVM-RFE) was performed. The 4,952 transcripts that passed initial filtering criteria were used as a starting point for moderated t-tests using R package “limma”; genes with false discovery rate (FDR) < 0.05 and absolute fold change ≥1.35 were retained. A cut-off of 1.35 was based on reports that gene changes starting at 1.3-fold using microarray can be reliably confirmed by real-time PCR (Wurmbach et al., 2001; Zhou et al., 2007; Huggins et al., 2008). Next, Multiple Support Vector Machine Recursive Feature Elimination (mSVM-RFE) (Duan et al., 2005) was used to identify the smallest subset of features with maximal classification accuracy. SVM-RFE (Guyon et al., 2002) is an iterative algorithm that works backward from an initial set of features. At each round, it first fits a simple linear SVM, then ranks the features based on their weights in the SVM solution, and finally eliminates the feature with the lowest weight. mSVM-RFE extends this idea by using resampling techniques at each iteration to stabilize the feature rankings. We began by using the recursive procedure of Duan et al. (2005) to compute the ranking score statistics for each feature, then the top 100 ranked features were selected for further analysis. We used the ranks to define nested subsets of features \( F_1 \subset F_2 \subset \ldots \subset F \), and determined the best subset of features with smallest generalization error by varying a single parameter: the number of features. Multiple runs of fivefold cross-validation were used for estimation of generalization error.

**FIGURE 2** | Unsupervised hierarchical clustering and principal component analysis (PCA) revealed distinctive blood mRNA transcriptional profiles separating cases from controls. Unsupervised hierarchical clustering of blood transcriptional profiles of women in training (A) and testing (B) datasets using 4952 transcripts. Samples were ordered by hierarchical clustering (Spearman correlation with average linkage) creating a condition tree, upper horizontal edge of heat map; study groupings (clinical phenotypes) are the colored blocks on the top of each profile. Heat map rows are genes; columns are participants. Principle component analysis of the variance in mRNA expression of the subjects depicted in the heat maps in training (C) and testing (D) datasets, using 4,952 transcripts and the same color scheme with each colored square depicting one subject. The x axis represents the first principal component, PC1, which accounts for the largest variance of mRNA expression, and the y axis, PC2, explains the second largest variance.
mSVM-RFE identified the smallest subset of 21-gene with maximal classification accuracy. For prediction, SVM with 21 candidate biomarkers was used with the training dataset to generate a prediction model and to determine predictive accuracy in the testing dataset and three independent, disease-related, datasets. Data were standardized; linear kernel was used in SVM. With the predicted probability of the binary response (elevated risk of PID vs. low risk), a cut point of 0.5 was used. Validation of mRNA transcripts was performed by interrogating total RNA from participants via nCounter assay and were analyzed using NSolver v.3.0 software (NanostringTM). Differential expression between cases and controls was identified using t-test.

Preservation Module, Gene Set Enrichment, and Pathway Analysis
Weighted Gene Coexpression Network Analysis (WGCNA) and a composite preservation statistic Z-summary (Langfelder et al., 2011) was used to determine if a module present in biopsy-confirmed cases was represented in biopsy-predicted TECH-N cases. Gene set enrichment analysis (GSEA) was performed to examine whether any preserved modules were significantly enriched in disease associated sectors generated by differential network analysis using WGCNA (Fuller et al., 2007; Luo et al., 2009; Zheng et al., 2018). Biological annotations of genes differing greatly between groups were explored with Ingenuity Pathway Analysis (IPA) (http://www.ingenuity.com/index.html). The significance of the canonical pathway was assessed using Fisher’s exact test. Multiple testing was adjusted by Benjamini–Hochberg. All analyses were conducted in R (version 3.1.2).

RESULTS
Training and Testing Dataset Patient Characteristics
Table 1 summarizes the distribution of demographic, clinical and microbiological characteristics of study participants assigned to training and testing datasets. Age, race, education, insurance, contraceptive status, bacterial vaginosis, or infection with Trichomonas vaginalis did not differ significantly between the cases and controls in either dataset (p > 0.05).

Transcriptional Profiles Define Patients With STI-Induced PID
Unsupervised hierarchical clustering was conducted in training and testing datasets to determine if profiles grouped according to disease (Figure 2), and to visualize gene expression patterns. In the training dataset, transcriptional response profiles for 7 of 9 cases clustered tightly, and were easily distinguished from controls (N = 18). In the testing dataset, 4 out of 5 cases clustered and were distinct from 9 of 10 controls. Principal component analysis separated participants in a pattern consistent with the hierarchical clusters, with variance explained by the first principle component 61% and the second principle component 15%. These findings confirm that CT/GC-induced PID elicits a distinct blood transcriptional profile (Zheng et al., 2018).

Table 2 | A list of 21 classifiers of STI PID using blood gene expression arrays.

| Gene   | Adjusted P-value | P-value | Fold change (case vs. control) |
|--------|------------------|---------|-------------------------------|
| AIM2   | 1.31E-05         | 1.32E-08| 2.06                          |
| DSC2   | 1.65E-05         | 3.02E-08| 2.3                           |
| SIGLEC5| 1.65E-05         | 2.81E-08| 1.97                          |
| CASP1  | 1.57E-05         | 6.99E-08| 1.58                          |
| CD58   | 1.67E-05         | 5.34E-08| 1.53                          |
| GBP2   | 1.67E-05         | 7.90E-08| 1.47                          |
| RNF19B | 1.67E-05         | 8.15E-08| 1.44                          |
| LIN7A  | 4.47E-05         | 5.87E-07| 1.6                           |
| ADM    | 4.38E-05         | 7.22E-07| 2.48                          |
| NAMPT  | 5.65E-05         | 1.08E-06| 2.09                          |
| LOC440731| 6.76E-05   | 1.48E-06| 1.61                          |
| CYB6R4 | 6.46E-05         | 1.56E-06| 1.46                          |
| PLAUR  | 9.69E-05         | 2.93E-06| 1.56                          |
| FAS    | 0.00022          | 1.30E-05| 1.39                          |
| LYSDM2 | 0.000698        | 8.78E-05| 1.4                           |
| RPS15A | 0.009756         | 0.00032 | 1.35                          |
| DOWNREGULATED |
| FAIM3  | 1.87E-05         | 8.15E-08| −1.89                         |
| CD79A  | 3.30E-05         | 3.29E-07| −1.96                         |
| TCL1A  | 6.67E-05         | 1.41E-06| −1.85                         |
| EEF1D  | 0.000134         | 5.55E-06| −1.54                         |
| TSPAN3 | 0.001352         | 0.00025 | −1.35                         |

Classifier Genes Accurately Diagnose Women With STI-Induced Endometritis
Feature selection identified 21 genes (Table 2) that were used as classifiers in an SVM model and 10-fold cross-validation was conducted to determine their performance in the training dataset. Cross-validation achieved 100% accuracy, with 27 out of 27 patients correctly classified. Sensitivity, specificity, and overall predictive accuracy was 100% with the area under the receiver operating characteristic (ROC) curve = 1 (data not shown). We then determined the predictive performance of the panel in an independent testing dataset (Figure 3). Biomarker sensitivity was 100% (5 of 5 women with upper genital tract STI-induced endometritis were predicted as positive; 95% CI 80%, 100%), specificity was 80% (8 of 10 women who were negative for upper genital tract STI-induced endometritis by biopsy were predicted as negative; 95% CI 55%, 93%), and the overall predictive accuracy was 86.7% (13 of 15) with the area under the ROC curve = 0.96. Direction and magnitude of differential gene expression between cases and controls were validated for the training (P < 0.001 for all 21 genes) and testing datasets (P < 0.1 for all 21 genes) using nCounter expression array (Table 3).

The 21-gene panel includes genes present in immune response pathways we reported as dysregulated in women with STI-induced endometritis (Zheng et al., 2018). The top up-regulated genes in the biomarker panel are involved in interferon signaling (AIM2, GBP2, CASP1, NAMPT, RNF19b), myeloid...
cell-mediated inflammation (ADM, LYSMD2, CD58, LIN7A, SIGLEC5, PLAUR), and cell death (DSC2, CYB5R4, FAS). The top down-regulated genes are involved in cell adhesion and migration (TSPAN3), protein synthesis (EEF1D), and lymphocyte signaling (TCL1A, CD79A, FAIM3).

Utility of the Biomarker for Diagnosing Subclinical STI-Induced Endometritis

We evaluated the ability of the biomarker panel to diagnose subclinical STI-induced endometritis in asymptomatic women with endometrial infection and histologic evidence of endometritis (Figure 4). Among 12 asymptomatically infected women with endometritis, six had high cervical CT burden. The biomarker correctly identified STI-induced endometritis in 5 (83.3%). However, no women with low cervical CT burden were predicted positive. To determine if high cervical bacterial load drives the transcriptional signature, we compared gene expression levels in a group of women with normal histology and cervix-limited CT who differed only with respect to high (N = 5) vs. low burden (N = 11). No genes were significantly differentially expressed (FDR ≥ 0.3) after multiple comparison correction, revealing high CT burden was insufficient to drive the transcriptional signature. These data demonstrated the biomarker’s ability to detect endometritis in women with elevated cervical CT burden, in the absence of symptoms.

The Biomarker Can Discriminate Between STI-Induced Endometritis and Pelvic Pain Without STI

Next, we evaluated the biomarker in a group of women with pelvic pain and tenderness consistent with a PID diagnosis (Workowski et al., 2015) but without STI. Endometrial biopsies revealed normal histology (n = 8) or chronic endometritis
FIGURE 4 | Predicted probability using 21-gene signature and SVM of STI-induced endometritis in a target dataset of asymptomatic subjects with biopsy proven subclinical CT/GC-induced endometritis. Each dot represents one subject. The x-axis indicates the log10 cervical C. trachomatis load and the y-axis indicates the predicted probability of STI-induced endometritis. 

FIGURE 5 | Predicted probability using 21-gene signature and SVM of STI-induced endometritis in a dataset of women who were symptomatic but were uninfected. Subsets of patients within the dataset were positive and negative for histologic endometritis. Each dot represents one subject. The x-axis indicates two groups of women with pelvic pain without STI. One group has normal histology, the other group has chronic endometritis; y-axis indicates the predicted probability of STI-induced endometritis.

(\(n = 7\)) (Figure 5). All 8 women with pelvic pain and normal histology were predicted negative (100% specific), and 5 of 7 uninfected women with pelvic pain and chronic endometritis due to undetermined cause were predicted negative (71.4% specific). These data demonstrated the ability of the biomarker to discriminate women with STI-induced endometritis with 86.7% specificity overall.

STI-Induced Endometritis Modules Are Preserved in a Cohort of Women Predicted Positive by the Biomarker

The biomarker was evaluated in 42 TECH-N study participants (Trent et al., 2016). All TECH-N participants were diagnosed with clinical PID; 15 had documented CT and/or GC infection. Almost all participants were African American (98%) with a median age of 19 years. Of the 42 women, 23.8% were predicted positive for STI-induced endometritis. Among the 15 women with cervical STI, 6 (40%) were predicted positive: 3 of 3 with GC infection (100%) and 3 of 12 with CT (25%). In contrast, 4 of 27 women without STI (14.8%) were predicted positive.

The absence of upper genital tract microbiological and histological data for this cohort prevented direct evaluation of biomarker accuracy. However, we performed an indirect assessment by determining if the gene expression profiles of the 8 predicted cases showed conservation of 14 module networks (highly correlated genes) identified in 14 biopsy-confirmed cases (Zheng et al., 2018). Preservation analysis revealed that 8 modules yielded a zSummary statistic > 10, reflecting strong conservation (Figure 6). We also performed differential network analysis using WGCNA to detect significant and concordant differences between biopsy-confirmed cases and controls and between predicted cases and controls (Table 4, significance of module enrichment in sectors determined by GSEA). Five modules were differentially expressed (FDR < 0.05, Table 4) between combined sets of biopsy-confirmed cases (\(n = 14\)) and controls (\(n = 28\)). The top 4 modules were also differentially expressed (FDR < 0.05, Table 4) between predicted TECH-N cases (\(n = 8\)) and predicted controls (\(n = 23\)). Functional annotation of these modules (Table 4) was performed as before using IPA. STI-induced endometritis-associated genes and activated pathways detailed previously were replicated with overexpression of genes in myeloid cell and NF-\(\kappa\)B activation pathways and integrin-linked kinase signaling; and suppression of T cell specific genes, and genes for protein synthesis and mitochondrial oxidative phosphorylation (Zheng et al., 2018). These findings indicated that the predicted cases recapitulated the STI-induced endometritis profile of biopsy-confirmed cases, providing further evidence that the biomarker reflects gene changes that occur in patients with STI-induced endometritis.

The Biomarker Distinguishes STI-Induced Endometritis From Other Infectious and Inflammatory Conditions

The differential diagnosis of PID includes pain due to endometriosis, appendicitis, urinary tract infection, ovarian torsion, interstitial cystitis, and, less commonly, adnexal tumors. Of these diseases, transcriptional profiles were only available for appendicitis. The biomarker correctly identified 15 of 20 appendicitis patients (75%) as negative for STI-induced endometritis. Interestingly, patients with tuberculosis displayed substantial change compared to their healthy controls leading to
findings by generating a biomarker that can identify women at high risk for STI-induced endometritis. We identified a 21 gene-panel that accurately identified symptomatic women with upper genital tract CT/GC and inflammation. This panel also accurately identified asymptomatic women with cervix-limited infection and uninfected women as controls, suggesting that the biomarker is not driven by cervical infection. We were able to determine STI-induced endometritis with 83.3% accuracy in asymptomatic women with high cervical CT burden. This demonstrates the ability of the biomarker to detect women with CT-induced, subclinical endometritis but the panel failed to identify women with low cervical burden who had endometritis, indicating that diagnostic sensitivity is positively associated with bacterial load. This suggests that the biomarker identifies women experiencing hyperinflammation (peak illness), while mild or moderate inflammation (initial or recovery phase) may be undetectable. This lack of sensitivity likely reflects restriction of CT infection to the reproductive tract mucosa. Since over 90% of CT infections are asymptomatic in women, identification of enhanced risk for endometritis in any infected woman, regardless of burden, would enhance clinical care by providing the patient with information related to their risk of long-term sequelae.

The biomarker correctly identified 100% of women with pelvic pain without infection and without endometritis as negative. Two of 7 STI-uninfected symptomatic women with chronic endometritis were predicted as cases. These misclassifications could reflect PID from infection by microorganisms not evaluated here (Haggerty et al., 2016) or recent resolution of STI before enrollment with residual endometritis. Six of seven had documented GC or CT infection history and two reported prior PID. In addition, using an independent cohort of women with clinically diagnosed PID and cervical CT/GC, the biomarker predicted 40% to have endometritis. This percentage is consistent with morbidity rates after PID (Price et al., 2013). Furthermore, disease-related modules differentially expressed in biopsy-confirmed cases and controls were also differentially expressed in biomarker-predicted cases and controls.

The biomarker successfully distinguished women with STI-induced endometritis from patients with streptococcal or staphylococcal infection, and lupus. Examination of pre-defined blood modular signatures has revealed that patients with lupus and streptococcal infection do not exhibit elevated inflammation transcripts (Berry et al., 2010) while patients with staphylococcal infection demonstrated enhanced inflammation transcripts but minimal change in IFN-inducible transcripts, and B- and T cell transcripts. STI-induced endometritis contrasted with all groups, characterized by enhanced inflammatory transcripts, including IFN-responsive genes, with significantly decreased T cell transcripts (Zheng et al., 2018). However, the biomarker was unable to reliably distinguish tuberculosis from STI-induced endometritis. The blood-derived modular signature of tuberculosis was paralleled in STI-induced endometritis, including enhanced IFN-inducible genes, myeloid inflammatory response genes, and decreased T cell transcripts. Fortunately, our biomarker was quite accurate at distinguishing STI-induced endometritis from appendicitis, which is in the differential diagnosis. The decrease in interferon signaling genes in

### DISCUSSION

We previously characterized distinct blood mRNA profiles in STI-induced endometritis (Zheng et al., 2018) that indicated a pathway for biomarker discovery. We have extended our

![FIGURE 6](Image)
**TABLE 4** | Preservation and functional annotation of significantly differentially expressed modules between cases and controls by Gene Set Enrichment Analysis (GSEA).

| Module   | Preservation Zsummary | FDR* (biopsy-confirmed cases vs. controls) | FDR (predicted cases from Tech-N vs. controls) | Enriched ingenuity canonical pathways                      |
|----------|-----------------------|--------------------------------------------|-----------------------------------------------|------------------------------------------------------------|
| Turquoise| 32                    | 1.58E-84                                   | 5.75E-15                                      | Overexpression of myeloid cell genes                        |
| Yellow   | 20                    | 2.47E-34                                   | 6.29E-14                                      | Suppression of T-cell specific genes                        |
| Brown    | 28                    | 4.07E-21                                   | 3.55E-10                                      | Suppression of protein synthesis and mitochondrial oxidative phosphorylation |
| Midnight Blue | 8             | 3.64E-06                                   | 2.46E-02                                      | Overexpression of NF-κB and Integrin-linked kinase signaling |
| Purple   | 19                    | 1.76E-03                                   | ***NS                                         | Suppression of cell cycle control and regulation           |

*FDR, False discovery rate; ***NS, Not significant (FDR > 0.05).

**FIGURE 7** | The 21-gene biomarker distinguishes STI-induced endometritis from other infectious and inflammatory conditions. (A) The number of samples within each disease and control group predicted as STI-induced endometritis is summarized in the table. (B) The predicted probability of STI-induced endometritis in each disease and control group using a 21-gene biomarker. Each dot represents one subject. The x-axis indicates the groups of subjects and y-axis indicates the predicted probability of STI-induced endometritis. The dotted line corresponds to a predicted probability cutoff of 0.5. (C) Unsupervised hierarchical clustering using 21-genes revealed distinctive blood mRNA transcriptional profiles separating STI-induced endometritis from other diseases and controls. Study groupings (clinical phenotypes) are the colored blocks on the top of each profile. Heat map rows are genes; columns are participants. Transformed expression levels are indicated by color scale, with red representing relative high expression and blue relative low expression.

appendicitis patients likely provides increased specificity. In sexually active females presenting with abdominal pain, a negative result with the biomarker would suggest possible appendicitis rather than endometritis.

Limitations of our study included small sample size and absence of longitudinal data regarding development of reproductive tract sequelae in women predicted to have STI-induced endometritis. A large independent cohort is warranted to validate the sensitivity and specificity. The biomarker was unable to detect women with endometritis who had low cervical bacterial burden, indicating the potential to miss women at risk for sequelae who may be in the early...
### TABLE 5 | Top 10 up-regulated pathways in acute appendicitis patients vs. controls with non-specific abdominal pain.

| Canonical pathways                                      | FDR (BH)** | Ratio*** | Molecules                                                                 |
|---------------------------------------------------------|------------|----------|---------------------------------------------------------------------------|
| 3-phosphoinositide biosynthesis                         | 1.51E-05   | 0.1      | PPFIBP2, PIP4KB, PPP4R1, HACD2, PTPN12, UBLCP1, SACM1L, PTPN12, MTNR1B, PTPN12, ATM |
| Production of nitric oxide and reactive oxygen species in macrophages | 3.31E-05   | 0.0979   | RAP1B, MAP3K1, IFNGR1, NCF4, JAK2, IFI1, TI2R, PPP1CC, LYZ, RHOQ, ROHB, PPP1R12A, CAT, NCF2, CYBB, ATM |
| Inflammasome pathway                                    | 3.72E-05   | 0.3      | IL18, NLRP3, AIM2, CASP1, CTSS, CASP5                                     |
| ILK signaling                                            | 4.07E-05   | 0.0964   | PXN, PDK1, VIM, HIF1A, CREB5, PTKN, NCF2, MYC, RHOQ, ROHB, PPP1R12A, LIMS1, CDC42, PIK3CG, CREB1, RSU1, ITG5, ATM |
| Role of pattern recognition receptors in recognition of bacteria and viruses | 6.17E-05   | 0.109    | NLRP3, RNASEL, TLR2, IFI1, CLEC7A, IL18, TLR5, PIK3CG, CREB1, CASP1, OSM, IFN2, ATM |
| PI3K/AKT signaling                                      | 8.32E-05   | 0.112    | YWHAG, ITGA5, NLRP3, CASP1, PTEN, YWHAG, HSP90B1, LIM1, PIK3CG, HSP90A, CDK1, ITG5, ATM |
| PI3K/AKT signaling                                      | 0.000204   | 0.05754  | TLR2, TREM1, IL18, NLRP3, TLR5, LIM1, CASP1, ITGA5, JAK2, CASP5           |
| Fcy receptor-mediated phagocytosis in macrophages and monocytes | 0.000295   | 0.118    | NCK2, PXN, ACTR3, CBL, FCGR2A, CDC42, PIK3CG, ARPC5, FYB1, PRKCA, PTEN |
| Integrin signaling                                      | 0.000479   | 0.0822   | RAP1B, PXN, ASAP1, ARPC5, ITGA5, ATG2, PTKN, NCF2, WIP1F, RHOQ, ACTR3, ROHB, PPP1R12A, LIMS1, CDC42, PIK3CG, NEDD9, ITG5, ATM |
| Phagosome maturation                                     | 0.010715   | 0.0946   | TUBB1, DCTN4, VPS41, CTSO, TUBB2A, TUBA4A, ATP6V1A, LAMP2, CTS1, HLA-DRB3, NOF2, CYBB, CTSS, CTSC |

*P-value: The p value identifies statistically significant over-representation of focus genes in a given process. Over represented functional or pathway processes are processes which have more focus genes than expected by chance.

**False Discovery Rate by Benjamini-Hochberg procedure.

***Ratio: The ratio indicates the number of differentially expressed genes that map to the pathway divided by the total number of genes that map to the canonical pathway.

### TABLE 6 | Top 10 down-regulated pathways in acute appendicitis patients vs. controls with non-specific abdominal pain.

| Canonical pathways                                      | FDR (BH)** | Ratio*** | Molecules                                                                 |
|---------------------------------------------------------|------------|----------|---------------------------------------------------------------------------|
| Mitochondrial dysfunction                               | 0.000145   | 0.0468   | FS1, COX17, UCP2, ATP5D, OQCRH, NDUB, NDUFA12, NDUFA3                     |
| Systemic lupus erythematosus signaling                  | 0.000162   | 0.04     | CD3E, IL1R, SNRPF, IL6R, SNRPB2, SNRPN70, PLCD1, CD79A, HLA-F             |
| Calcium-induced T lymphocyte apoptosis                  | 0.000295   | 0.0758   | CD3E, ZAP70, PLCG1, ATP2A3, EP300                                          |
| Remodeling of epithelial adherens junctions             | 0.000363   | 0.0725   | RAB5C, ARPC1B, TUBA1C, TUBB, ACTG1                                         |
| Oxidative phosphorylation                               | 0.000417   | 0.055    | COX17, ATP5D, OQCRH, NDUB, NDUFA12, NDUFA3                                |
| CTLA4 signaling in cytotoxic T lymphocytes              | 0.001862   | 0.0505   | FYN, AP2M1, CD3E, ZAP70, PLCG1                                            |
| Interferon signaling                                    | 0.003548   | 0.0833   | IF6, PSMB8, BAX                                                            |
| EpoF2 signaling                                         | 0.003548   | 0.0317   | RPL4, RPS26, RPL17, RPS15A, RPS29, RPL10A, RPL10P                          |
| Caveolar-mediated endocytosis signaling                 | 0.003631   | 0.0563   | FYN, RAB5C, ACTG1, ITGAX                                                   |
| Antigen presentation pathway                            | 0.004571   | 0.0789   | PSMB8, CD74, HLA-F                                                         |

**False Discovery Rate by Benjamini-Hochberg procedure.

*P-value: The p value identifies statistically significant over-representation of focus genes in a given process. Over represented functional or pathway processes are processes which have more focus genes than expected by chance.

***Ratio: The ratio indicates the number of differentially expressed genes that map to the pathway divided by the total number of genes that map to the canonical pathway.

Phases of infection and inflammation, or are in a resolution phase.

PID diagnosis is based on clinical criteria and confounded by wide variation in symptoms. Furthermore, asymptomatic CT/GC-infected women may sustain endometrial infection and damaging inflammation (Wiesenfeld et al., 2012). No single test or combination of diagnostic indicators reliably identifies endometritis. The most specific criteria currently available include endometrial biopsy with histopathologic evidence of endometritis, transvaginal sonography or magnetic resonance imaging showing thickened, fluid-filled tubes with or without free pelvic fluid or tubo-ovarian complex, or Doppler studies suggesting pelvic infection (e.g., tubal hyperemia); or laparoscopic findings consistent with PID, although this also requires endometrial biopsy if no visual evidence of salpingitis is present (Workowski et al., 2015). Although endometrial biopsies
can be performed with a suction pipelle, this procedure is difficult to perform routinely in the clinic, and laparoscopies require general anesthesia.

The nCounter Dx Analysis system (NanoString) used to confirm the mRNA results in this study, provides rapid, reliable, inexpensive, and reproducible molecular sub-grouping of clinical samples (Northcott et al., 2012; Veldman-Jones et al., 2015; Masucci et al., 2016). Results of the assay can easily be available within 24–48 h of obtaining blood from the patient. A blood biomarker that informs the clinician and the patient that the patient has upper genital tract inflammation coincident with their lower genital tract STI indicates increased risk for long term sequelae. This knowledge may prompt more intensive screening for STIs in that patient, with a goal to prevent long-term sequelae. A biomarker of STI-induced endometritis may also be used to monitor the benefit of novel therapies ancillary to antibiotic treatment, such as steroids or other anti-inflammatory medications, or as an end point to evaluate vaccines. Newer larger cohort and longitudinal studies that include evaluation of long-term sequelae are warranted to validate this biomarker.

**AUTHOR CONTRIBUTIONS**

XJ designed the study and prepared the manuscript. CO designed the study and prepared the manuscript; She also oversaw preparation of specimens for analysis. WZ assisted with biostatistical analysis. TP and BT contributed to the preparation of the final manuscript submission. HW, SH, MT, and CG contributed to recruitment, clinical evaluation and diagnosis of study participants. GT assisted with biostatistical analysis. TD designed the study and prepared the manuscript.

**FUNDING**

This work was supported by the National Institutes of Health [U19 AI084024 and R33 AI098660 and AI119164 to TD; and U19 AI113170 to XZ; and the National Institute of Nursing Research NR013507 to MT].

**ACKNOWLEDGMENTS**

We thank the women who agreed to participate in the contributing studies: Allison Collins, Abi Jett, Melinda Petrina, Carol Priest, Ingrid Macio, and Lorna Rabe for their efforts collecting and processing samples; Antonio J. Amortegi and Giuliana Trucco for pathological assessments, the staff at the Allegheny County Health Department STD Clinic and staff of the Emergency Departments at Mercy Hospital of Pittsburgh and Magee-Womens Hospital of UPMC; the staff of the Center for Adolescent and Young Adult Health at Harriet Lane, Pediatric Emergency Department, and the Adult Emergency Department at Johns Hopkins Hospital; and the staff of the Genomics Cores at the University of Pittsburgh and the University of North Carolina for their efforts.

**REFERENCES**

Berry, M. P., Graham, C. M., McNab, F. W., Xu, Z., Bloch, S. A., Oni, T., et al. (2010). An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. *Nature* 466, 973–977. doi: 10.1038/nature09247

Bjarling, C., Osser, S., and Persson, K. (2012). *Mycoplasma genitalium* in cervicitis and pelvic inflammatory disease among women at a gynecologic outpatient service. *Am. J. Obstet. Gynecol.* 206, 476. e1–476.e8. doi: 10.1016/j.ajog.2012.02.036

Centers for Disease Control and Prevention. (2017). Sexually Transmitted Disease Surveillance 2016. Atlanta, GA: US Department of Health and Human Services.

Chawla, L. S., Toma, I., Davison, D., Vaziri, K., Lee, J., Lucas, R., et al. (2016). Acute appendicitis: transcript profiling of blood identifies promising biomarkers and potential underlying processes. *BMC Med. Genomics* 9:40. doi: 10.1186/s12920-016-0200-y

Duan, K. B., Rajapakse, J. C., Wang, H., and Azuaje, F. (2005). Multiple SVM-RFE for gene selection in cancer classification with expression data. *IEEE Trans. Nanobiosci.* 4, 228–234. doi: 10.1109/TNAN.2005.853657

Fuller, T. F., Ghazalpour, A., Aten, J. E., Drake, T. A., Luis, A. J., and, Horvath, S. (2007). Weighted gene coexpression network analysis strategies applied to mouse weight. *Mamm. Genome* 18, 463–472. doi: 10.1007/s00335-007-9043-3

Guyon, I., Weston, J., Barnhill, S., and Vapnik, V. (2002). Gene selection for cancer classification using support vector machines. *Mach. Learn.* 46, 389–422. doi: 10.1023/A:1012487302797

Haggerty, C. L., Totten, P. A., Tang, G., Astete, S. G., Ferris, M. J., Norori, J., et al. (2016). Identification of novel microbes associated with pelvic inflammatory disease and infertility. *Sex. Transm. Infect.* 92, 441–446. doi: 10.1136/sextrans-2015-052285

Huggins, C. E., Domenighetti, A. A., Ritchie, M. E., Khalil, N., Favaloro, J. M., Proietto, J., et al. (2008). Functional and metabolic remodeling in GLUT4-deficient hearts confers hyper-responsiveness to substrate intervention. *J. Mol. Cell. Cardiol.* 44, 270–280. doi: 10.1016/j.yjmcc.2007.11.020

Irizarry, R. A., Hobbs, B., Collin, F., Beazer-Barclay, Y. D., Antonellis, K. J., Scher, U., et al. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics* 4, 249–264. doi: 10.1093/biostatistics/4.2.249

Johnson, W. E., Li, C., and Rabinovic, A. (2007). Adjusting batch effects in microarray expression data using empirical Bayes methods. *Biostatistics* 8, 118–127. doi: 10.1093/biostatistics/kxj037

Kiviat, N. B., Wolfer-Hanssen, P., Eschenbach, D. A., Wasserheit, J. N., Paavonen, J. A., Bell, T. A., et al. (1990). Endometrial histopathology in patients with culture-proved upper genital tract infection and laparoscopically diagnosed acute salpingitis. *Am. J. Surg. Pathol.* 14, 167–175. doi: 10.1097/00000478-199002000-00008

Langfelder, P., Luo, R., Oldham, M. C., and Horvath, S. (2011). Is my network module preserved and reproducible? *PLoS Comput. Biol.* 7:e1001057. doi: 10.1371/journal.pcbi.1001057

Luo, W., Friedman, M. S., Shedden, K., Hankenson, K. D., and Woolf, P. J. (2009). GAGE: generally applicable gene set enrichment for pathway analysis. *BMC Bioinformatics* 10:161. doi: 10.1186/1471-2105-10-161

Masucci, G. V., Cesano, A., Hawtin, R., Janetzki, S., Zhang, J., Kirsch, I., et al. (2016). Validation of biomarkers to predict response to immunotherapy in cancer: volume I - pre-analytical and analytical validation. *J. Immunother. Cancer* 4:67. doi: 10.1186/s40425-016-0178-1

McGowin, C. L., and Anderson-Smits, C. (2011). *Mycoplasma genitalium*: an emerging cause of sexually transmitted disease in women. *PLoS Pathog.* 7:e1001324. doi: 10.1371/journal.ppat.1001324

Northcott, P. A., Shah, D. J., Remke, M., Cho, Y. J., Kool, M., Hawkins, C., et al. (2012). Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. *Acta Neuropathol.* 123, 615–626. doi: 10.1007/s00401-011-0899-7
Zheng, T. B., Gottlieb, S. L., and Darville, T. (2017). Status of vaccine research and development of vaccines for Chlamydia trachomatis infection. Vaccine. doi: 10.1016/j.vaccine.2017.01.023. [Epub ahead of print].

Price, M. J., Ades, A. E., De Angelis, D., Welton, N. J., Macleod, J., Soldan, K., et al. (2013). Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model. Am. J. Epidemiol. 178, 484–492. doi: 10.1093/aje/kws583

Reese, S. E., Archer, K. J., Therneau, T. M., Atkinson, E. J., Vachon, C. M., De Andrade, M., et al. (2013). A new statistic for identifying batch effects in high-throughput genomic data that uses guided principal component analysis. Bioinformatics 29, 2877–2883. doi: 10.1093/bioinformatics/btt480

Rein, D. B., Kassler, W. J., Irwin, K. L., and Rabisee, L. (2000). Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet. Gynecol. 95, 397–402. doi: 10.1097/00006250-200003000-00016

Russell, A. N., Zheng, X., O’Connell, C. M., Taylor, B. D., Wiesenfeld, H. C., Hillier, S. L., et al. (2016). Analysis of factors driving incident and ascending infection and the role of serum antibody in Chlamydia trachomatis genital tract infection. J. Infect. Dis. 213, 523–531. doi: 10.1093/infdis/jiv438

Trent, M., Chung, S. E., Gaydos, C., Frick, K. D., Anders, J., Huettner, S., et al. (2016). Recruitment of minority adolescents and young adults into randomised clinical trials: Testing the design of the Technology Enhanced Community Health Nursing (TECH-N) pelvic inflammatory disease trial. Eur. Med. J. Reprod. Health 2, 41–51. doi: 10.1016/j.jadohealth.2016.10.041

Veldman-Jones, M. H., Brant, R., Rooney, C., Geh, C., Emery, H., Harbron, C. G., et al. (2015). Evaluating robustness and sensitivity of the NanoString Technologies nCounter Platform to enable multiplexed gene expression analysis of clinical samples. Cancer Res. 75, 2587–2593. doi: 10.1158/0008-5472.CAN-15-0262

Wiesenfeld, H. C., Hillier, S. L., Meyn, L. A., Amortegui, A. J., and Sweet, R. L. (2012). Subclinical pelvic inflammatory disease and infertility. Obstet. Gynecol. 120, 37–43. doi: 10.1097/AOG.0b013e31825a6bc9

Zhou, Y., Cras-Ménéur, C., Ohsugi, M., Stormo, G. D., and Permutt, M. A. (2007). A global approach to identify differentially expressed genes in cDNA (two-color) microarray experiments. Bioinformatics 23, 2073–2079. doi: 10.1093/bioinformatics/btm292

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Zheng, O’Connell, Zhong, Poston, Wiesenfeld, Hillier, Trent, Gaydos, Tseng, Taylor and Darville. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.